Humacyte, Inc. (HUMA)

Humacyte's stock price experienced a significant decline of 65.92% over the past six months (October 2025 - March 2026). In October 2025, Humacyte announced a registered direct offering of approximately $60.0 million worth of common stock and warrants. In November 2025, the company reported its Q3 2025 financial results, with revenue remaining flat year-over-year and a significant drop in net income and EPS. In December 2025, Humacyte entered into a credit facility with an affiliate of Avenue Capital Group, providing up to $77.5 million in new financing. In March 2026, Humacyte announced its Q4 and full-year 2025 financial results, with Q4 2025 revenue missing analyst forecasts, leading to a drop in stock price. Also in March 2026, several analysts downgraded Humacyte's stock and significantly lowered price targets.

The available information does not indicate specific demand seasonality for Humacyte, Inc.'s products and services. Demand is primarily driven by ongoing medical needs rather than seasonal fluctuations.

Humacyte, Inc. is a biotechnology platform company focused on developing and manufacturing universally implantable, bioengineered human tissues. The company engineers human acellular vessels (HAVs) designed to be implanted without inducing a foreign body response or immune rejection. Its major product, Symvess, received FDA approval in December 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. Humacyte is also developing a portfolio of HAVs targeting various other vascular applications, including arteriovenous access for hemodialysis and peripheral arterial disease, both currently in late-stage clinical trials. Additional applications in preclinical development include pediatric heart surgery, coronary artery bypass grafting with plans for first-in-human study in H2 2026, and delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Humacyte, Inc. is headquartered in Durham, North Carolina, United States. The company has ongoing clinical programs and partnerships that extend into Europe and North America. Humacyte is also strategically expanding into international markets, including a purchase commitment for Symvess in Saudi Arabia and the submission of a Marketing Authorization Application for Symvess in Israel for arterial trauma repair.

Humacyte's brand reputation has been primarily influenced by its financial performance and analyst sentiment. The company's stock has seen a significant decline, and several analysts have downgraded their ratings and lowered price targets, reflecting cautious sentiment. An FDA Form 483 issued in April 2024 regarding manufacturing facility observations could have negatively impacted the company's reputation. However, the FDA subsequently approved Symvess in December 2024. Positive developments, such as the FDA approval of Symvess and strategic international expansion efforts, aim to build awareness and understanding of the technology among healthcare providers.

As of December 2025, Humacyte, Inc. has 151 institutional owners holding a total of 55,582,571 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, LLC, UBS Group AG, State Street Corp, Millennium Management LLC, Morgan Stanley, Woodline Partners LP, Citadel Advisors LLC, and Two Sigma Investments, LP. Fresenius Medical Care AG owns 9.5% of shares outstanding as of January 2026. Individual investors hold a substantial 59% stake in Humacyte, while institutions own 24% and public companies own 9.49%. Insiders own approximately $11 million worth of stock.